Market Size of Endoscopic Retrograde Cholangiopancreatography (ERCP) Industry
Study Period | 2019 - 2029 |
Market Size (2024) | USD 1.66 Billion |
Market Size (2029) | USD 2.45 Billion |
CAGR (2024 - 2029) | 7.97 % |
Fastest Growing Market | Asia Pacific |
Largest Market | North America |
Market Concentration | Medium |
Major Players*Disclaimer: Major Players sorted in no particular order |
Endoscopic Retrograde Cholangiopancreatography (ERCP) Market Analysis
The Endoscopic Retrograde Cholangiopancreatography Market size is estimated at USD 1.66 billion in 2024, and is expected to reach USD 2.45 billion by 2029, growing at a CAGR of 7.97% during the forecast period (2024-2029).
COVID-19 impacted the studied market due to cancellations of elective procedures including endoscopy and other surgical procedures. Endoscopy providers were at high risk during the pandemic since the disease spreads mostly by direct touch or aerosol droplets, and endoscopic procedures necessitate a close physical distance between patients and medical professionals. For instance, the study published in Endoscopy International Journal in April 2021, reported that ERCP case volume was reduced by 44.1% during the initial months of the pandemic compared to the previous year. However, the market recovered in the last few years due to the rising demand for minimally invasive endoscopic procedures and is expected to register stable growth during the forecast period.
The studied market is expected to grow during the forecast period because of the rising incidence of pancreatic cancer, rising preference for minimally invasive surgeries, and technological advancements in devices.
The introduction of minimally invasive surgical techniques has increased the number of patients seeking ERCP operations, which will help the industry thrive in the coming years. As per the American Cancer Society's annual report published in January 2023, an estimated 41,210 new cases of liver cancer are expected to be diagnosed in the US. The most common types of liver cancer are hepatocellular carcinoma (72%) and intrahepatic bile duct cancer (cholangiocarcinoma; 19%). The high burden of cholangiocarcinoma and hepatocellular carcinoma is expected to boost the demand for endoscopic retrograde cholangiopancreatography for the early detection of such malignancies.
Various healthcare organizations adopt initiatives like partnerships for the research and development of innovative products, thereby leading to market growth. For instance, as per a research article published in Optica Publishing Group journal in July 2022, researchers from the School of Biomedical Engineering & Imaging Sciences created a photoacoustic imaging endoscope probe that can fit inside a medical needle with an inner diameter of just 0.6 millimeters. The scientists also claimed that artificial intelligence could be used to speed up imaging procedures
The ultra-thin endoscope was developed in collaboration between King's College London and University College London. The device allows the 3D characterization of tissue during various minimally invasive procedures such as tumor biopsies. Such research studies leading to the development of advanced products are expected to create opportunities for market players to develop and market innovative products boosting market growth.
Furthermore, the strategic initiatives adopted by the market players, such as product launches, mergers, and acquisitions, are anticipated to drive the market over the forecast period. For instance, in April 2022, Olympus entered into a strategic distribution agreement with EndoClot Plus. EndoClot Plus develops technologies in the hemostasis space, including the EndoClot PHS, a nonthermal, nontraumatic method for achieving hemostasis with GI bleeds designed to help gastroenterologists stop bleeding rapidly and reliably. Also, in October 2021, Olympus Corporation (Japan) revealed the debut of two therapy devices, StoneMasterV and VorticCatchV, to improve the effectiveness of bile duct stone management and retrieval for ERCP. Such launches are anticipated to accelerate market growth during the forecast period.
Thus, owing to the aforementioned factors, the market is expected to show growth over the forecast period. However, the high price associated with ERCP devices restrained the market over the forecast period.
Endoscopic Retrograde Cholangiopancreatography (ERCP) Industry Segmentation
As per the scope of the report, endoscopic retrograde cholangiopancreatography is a procedure that combines endoscopy and fluoroscopy to identify and treat biliary and pancreatic ductal system disorders.
The Endoscopic Retrograde Cholangiopancreatography (ERCP) Market is Segmented by Product (Endoscopes, Endotherapy Devices (Sphincterotomes, Lithotripter, Stents, and Other Endotherapy Devices), Visualization Systems, Energy Devices, and Other Products), Procedures (Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation, Pancreatic Sphincterotomy, Pancreatic Duct Stenting, and Pancreatic Duct Dilatation), End User (Hospitals, Ambulatory Surgery Centre's and Clinics, Other End Users), Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the market size in value terms in USD for all the abovementioned segments.
By Product | ||||||
Endoscope | ||||||
| ||||||
Visualization Systems | ||||||
Energy Devices | ||||||
Other Products |
By Procedure | |
Biliary Sphincterotomy | |
Biliary Stenting | |
Biliary Dialtation | |
Pancreatic Sphincterotomy | |
Pancreatic Duct Stenting | |
Pancreatic Duct Dilatation |
By End User | |
Hospitals | |
Ambulatory Surgery Centers and Clinics | |
Other End Users |
Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Endoscopic Retrograde Cholangiopancreatography (ERCP) Market Size Summary
The Endoscopic Retrograde Cholangiopancreatography (ERCP) market is poised for significant growth over the forecast period, driven by the increasing incidence of pancreatic cancer, a rising preference for minimally invasive surgeries, and technological advancements in medical devices. The market experienced a temporary setback due to the COVID-19 pandemic, which led to the cancellation of elective procedures, including endoscopies. However, the demand for minimally invasive procedures has rebounded, supporting market recovery and growth. The introduction of advanced surgical techniques and devices has expanded the patient base seeking ERCP operations, further propelling market expansion. Collaborative efforts among healthcare organizations to develop innovative products, such as ultra-thin endoscopes and AI-enhanced imaging tools, are expected to create new opportunities for market players.
The North American region is anticipated to hold a significant share of the ERCP market, supported by substantial research and development investments, the presence of key market players, and a high prevalence of pancreatic and gallbladder diseases. Strategic initiatives, including product launches, mergers, and acquisitions, are expected to drive regional market growth. The market is characterized by intense competition, with global players focusing on differentiating their endoscopic systems through optimized visualization and operative capabilities. Key industry participants, such as Olympus Corporation, CONMED Corporation, and Fujifilm Holdings Corporation, are actively engaging in strategic activities to enhance their market position and expand their product offerings.
Endoscopic Retrograde Cholangiopancreatography (ERCP) Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Rising Incidence of Pancreatic Cancer
-
1.2.2 Rising Preference for Minimally Invasive Surgeries and Technological Advancements
-
-
1.3 Market Restraints
-
1.3.1 High Costs of Endoscopic Retrograde Cholangiopancreatography Devices
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD million)
-
2.1 By Product
-
2.1.1 Endoscope
-
2.1.2 Endotherapy Devices
-
2.1.2.1 Sphincterotomes
-
2.1.2.2 Lithotripter
-
2.1.2.3 Stents
-
2.1.2.4 Other Endotherapy Devices
-
-
2.1.3 Visualization Systems
-
2.1.4 Energy Devices
-
2.1.5 Other Products
-
-
2.2 By Procedure
-
2.2.1 Biliary Sphincterotomy
-
2.2.2 Biliary Stenting
-
2.2.3 Biliary Dialtation
-
2.2.4 Pancreatic Sphincterotomy
-
2.2.5 Pancreatic Duct Stenting
-
2.2.6 Pancreatic Duct Dilatation
-
-
2.3 By End User
-
2.3.1 Hospitals
-
2.3.2 Ambulatory Surgery Centers and Clinics
-
2.3.3 Other End Users
-
-
2.4 Geography
-
2.4.1 North America
-
2.4.1.1 United States
-
2.4.1.2 Canada
-
2.4.1.3 Mexico
-
-
2.4.2 Europe
-
2.4.2.1 Germany
-
2.4.2.2 United Kingdom
-
2.4.2.3 France
-
2.4.2.4 Italy
-
2.4.2.5 Spain
-
2.4.2.6 Rest of Europe
-
-
2.4.3 Asia-Pacific
-
2.4.3.1 China
-
2.4.3.2 Japan
-
2.4.3.3 India
-
2.4.3.4 Australia
-
2.4.3.5 South Korea
-
2.4.3.6 Rest of Asia-Pacific
-
-
2.4.4 Middle-East and Africa
-
2.4.4.1 GCC
-
2.4.4.2 South Africa
-
2.4.4.3 Rest of Middle-East and Africa
-
-
2.4.5 South America
-
2.4.5.1 Brazil
-
2.4.5.2 Argentina
-
2.4.5.3 Rest of South America
-
-
-
Endoscopic Retrograde Cholangiopancreatography (ERCP) Market Size FAQs
How big is the Endoscopic Retrograde Cholangiopancreatography Market?
The Endoscopic Retrograde Cholangiopancreatography Market size is expected to reach USD 1.66 billion in 2024 and grow at a CAGR of 7.97% to reach USD 2.45 billion by 2029.
What is the current Endoscopic Retrograde Cholangiopancreatography Market size?
In 2024, the Endoscopic Retrograde Cholangiopancreatography Market size is expected to reach USD 1.66 billion.